Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation

GOTHENBURG, Sweden, April 29, 2010 /PRNewswire/ -- Albireo today announced that additional clinical data will be reported from a recent study assessing the safety, tolerability and efficacy of A3309 in patients with chronic constipation. A3309 is a first-in-class investigational compound for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). The results will be presented during the 2010 Digestive Disease Week (DDW) annual meeting being held in New Orleans, US.